EZH2-regulated immune risk score prognostic model predicts outcome of clear cell renal cell carcinoma.

ABSTRACT:

Background

The enhancer of zeste homolog 2 (EZH2) plays an important role in the tumor microenvironment (TME), and EZH2 in shaping the epigenetic landscape of CD8⁺ T cell fate and function, with a particular emphasis on cancer. Here, high EZH2 expression always leads to less CD8⁺ T cell infiltration. However, clear cell renal cell carcinoma (ccRCC) is reportedly a "hot" tumor, with contradictory high EZH2 expression. Our goal was to construct a EZH2-regulated immune risk score prognostic model to predict ccRCC outcomes, and provide a prospect of clinical EZH2 inhibitors in fine-tuning T cell responses with immune therapy.

Methods

We downloaded and analyzed The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE), TISIDB database, and WebGest

SUBMITTER: Xu S 

PROVIDER: S-EPMC9906105 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature